Amgen Reports Phase 3 subgroup analysis Data for Ribociclib in Mucopolysaccharidosis

Amgen today announced Phase 3 subgroup analysis results for Ribociclib in patients with Mucopolysaccharidosis. The study demonstrated that Ribociclib reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Mucopolysaccharidosis and support the continued development of Ribociclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ribociclib was consistent with previous observations, with no new safety signals identified.